Solid tumor target-immunotherapy with novel biomimetic immuno- chemotherapy composite mesoporous silica nanoparticles coated by the CD80 modified cell membranes

Abstract New strategies enhancing both cellular immune response and targetability of tumor immunomodulator remain a major challenge for the immunotherapy in the solid tumor. In this research, a novel biomimetic immuno-chemotherapy composite nanoparticle system was designed as a breast tumors targeted drug. The cell membranes were modified by the glycosyl-phosphatidylinositol (GPI) anchored anti-HER2 single chain variable fragment (scFv) and the GPI anchored co-stimulatory molecule CD80; and the membranes was coated on mesoporous silica nanoparticles loaded with Doxorubicin (DOX). The effects of as-prepared therapeutic system in initiating both tumor targetability and cellular immune response were investigated through in vitro and in vivo experiments. The results showed that therapeutic system greatly promoted the CD8+ T-cell activation and the cytokine production; and reduced the myeloid-derived suppressor cells (MDSCs) levels in tumors. This novel biomimetic therapeutic system can significantly promote immunomodulatory and antitumor activity in vitro and in vivo experiments.